Document Type : Original Article


1 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

2 Clinic of Hematology, Ali-Asghar Hospital, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4 Immune and Gene Therapy Lab, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden

5 Monoclonal Antibody Research Center, Avesina Research Institute, Tehran, Iran

6 National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran


Background: The Wilm’s tumor gene 1 (WT1) encodes a zinc finger transcription factor that is inactivated in a subset of Wilm’s tumors. It plays a crucial role in growth, proliferation and development of some embryonic and adult organs. WT1 is expressed as a tumor associated antigen (TAA) in various types of solid and hematopoietic malignancies and can be employed as a useful marker for targeted immunotherapy and monitoring of minimal residual disease (MRD).
Objective: To investigate the profile of WT1 gene expression in Iranian patients with acute myeloblastic leukemia.
Methods: RT-PCR method was used to determine the WT1 gene expression in bone marrow (BM) and/or peripheral blood (PB) samples from 11 patients with AML and PB samples of 36 normal subjects. Isolated cells from all patients were immunophenotyped by flow cytometry.
Results: The leukemic cells from 10 patients (91%) were found moderately or strongly positive for WT1 expression whereas only 3 out of 36 normal subjects expressed WT1 at very low levels. A highly significant correlation was observed for WT1 expression between paired BM and PB samples of the AML patients.
Conclusion: Our results indicate that WT1 is expressed in the majority of Iranian AML patients and may be employed for screening and monitoring of minimal residual disease in these patients.